Publications
US Regulatory Landscape not Improving for Ultra-Rare Disease Therapies
Quoted, BioWorld
Chad Landmon, Hatch-Waxman & Biologics Chair, offers insight on the U.S. development path for rare disease treatment.
Chad Landmon, Hatch-Waxman & Biologics Chair, offers insight on the U.S. development path for rare disease treatment.